You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

Claims for Patent: 10,857,102

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,857,102

Title:	Therapeutic compositions comprising rilpivirine HCL and tenofovir disoproxil fumarate
Abstract:	The invention provides multilayer tablets that contain rilpivirine hydrochloride, emtricitabine, and tenofivir disoproxil fumarate. The tablets are useful for the treatment of HIV.
Inventor(s):	Oliyai; Reza (Burlingame, CA), Wiser; Lauren (Cupertino, CA), Menning; Mark (San Francisco, CA)
Assignee:	Gilead Sciences, Inc. (Foster City, CA) Janssen Sciences Ireland UC (Little Island, IE)
Application Number:	13/988,072
Patent Claims:	1. A tablet comprising a first layer and a second layer, wherein the first layer consists of 27.5 mg rilpivirine HCl, 60.0 mg microcrystalline cellulose, 189.8 mg lactose monohydrate, 3.3 mg povidone, 0.4 mg polysorbate 20, 16.1 mg croscarmellose sodium, and 3.0 mg magnesium stearate; and the second layer consists of 200.0 mg emtricitabine, 300.0 mg tenofovir disoproxil fumarate, 150.0 mg microcrystalline cellulose, 80.0 mg lactose monohydrate, 50.0 mg pregelatinized starch, 60.0 mg croscarmellose sodium, and 10.0 mg magnesium stearate. 2. A tablet comprising a first layer, a second layer, and a third layer that is between and that separates the first layer and the second layer, wherein the first layer consists of 27.5 mg rilpivirine HCl, 60.0 mg microcrystalline cellulose, 189.8 mg lactose monohydrate, 3.3 mg povidone, 0.4 mg polysorbate 20, 16.1 mg croscarmellose sodium, and 3.0 mg magnesium stearate; the second layer consists of 200.0 mg emtricitabine, 300.0 mg tenofovir disoproxil fumarate, 150.0 mg microcrystalline cellulose, 80.0 mg lactose monohydrate, 50.0 mg pregelatinized starch, 60.0 mg croscarmellose sodium, and 10.0 mg magnesium stearate; and the third layer comprises 150.+-.8.0 mg of microcrystalline cellulose or lactose monohydrate, or a mixture thereof. 3. A tablet having a first layer that consists of 27.5 mg rilpivirine HCl, 60.0 microcrystalline cellulose, 189.8 mg lactose monohydrate, 3.3 mg povidone, 0.4 mg polysorbate 20, 16.1 mg croscarmellose sodium, and 3.0 mg magnesium stearate; a second layer that consists of 200.0 mg emtricitabine, 300.0 mg tenofovir DF, 150.0 mg microcrystalline cellulose, 80.0 mg lactose monohydrate, 50.0 mg pregelatinized starch, 60.0 mg croscarmellose sodium, and 10.0 mg magnesium stearate; and 34.5 mg of a film coating. 4. The tablet of claim 1, wherein the tablet further comprises a film coating. 5. The tablet of claim 4, wherein the film coating comprises a hydrophilic polymer material.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.